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Background: Assessment of ischemia for patients who undergone orthotopic heart transplantation (OHT) is an important step in the post-
transplant management. After heart transplantation, increased responsiveness to the negative dromotropic and chronotropic effects of adenosine 
has been reported. Regadenoson (REG) is a newer pharmacological stress agent which has been tested in a large population of individuals for 
assessment of ischemic coronary disease with very small incidence of rhythm and/or conduction abnormalities. OHT patients were excluded so the 
safety of REG in this subgroup is unknown. 
Methods: Retrospective case series review of a tertiary care center experience of patients who undergone OHT and subsequently had REG 
myocardial perfusion imaging (MPI) study from the period of January-July 2009. 
Results: A total of 25 patients met the above criteria. REG bolus injection was well tolerated with no reported episode of AVB, significant 
hypotension or bradycardia. More importantly, when compared to previous database from our institution by Arida et al, of 102 OHT patients that 
underwent Adenosine MPI, significantly higher rates of conduction abnormalities were seen (p=0.01, Figure 1). 
Conclusion: To our knowledge, this is the first case series reporting the use of REG in patients who undergone OHT. REG seems to be safe and 
well tolerated in this special subgroup of patients without significant cardiovascular adverse events. Further prospective studies are needed to 
corroborate our findings.
